Mabwell to Present Clinical Study Results of Novel ADC 9MW2821 for Cervical Cancer at SGO Annual Meeting

Mabwell, a leading biopharmaceutical company, has announced that it will be presenting the results of a clinical study focusing on the efficacy and safety of their novel Nectin-4-targeting ADC 9MW2821 for patients with recurrent or metastatic cervical cancer. The presentation is scheduled to take place at the Society of Gynecologic Oncology (SGO) annual meeting on women’s cancer in San Diego, USA.

The American Society of Gynecologic Oncology (SGO) is a renowned non-profit medical organization dedicated to the study, treatment, and education of gynecologic cancers, hosting the upcoming event where Mabwell will showcase their findings.

The plenary oral presentation, titled ‘Efficacy and safety of 9MW2821, an antibody-drug conjugate targeting Nectin-4, monotherapy in patients with recurrent or metastatic cervical cancer: A multicenter, open-label, phase I/II study,’ will be delivered by Huijuan Yang from Fudan University Shanghai Cancer Center at Ballroom 20AB on March 16, 2024, at 3:00 PM PDT.

9MW2821 stands out as a site-specific conjugated novel Nectin-4-targeting ADC developed by Mabwell through their advanced research and development capabilities. The drug’s mechanism involves specific binding to Nectin-4 on cell membranes, internalization, and release of cytotoxic agents to induce tumor cell apoptosis. Mabwell is actively conducting multiple clinical trials to assess the effectiveness of 9MW2821 in various indications, including cervical cancer and urothelial carcinoma.

Mabwell’s commitment to innovation is evident in their robust R&D system covering target discovery, clinical research, and manufacturing transformation. With 14 pipeline products at different developmental stages, Mabwell’s focus spans oncology, autoimmune diseases, metabolic disorders, ophthalmologic diseases, and infectious diseases. The company’s Taizhou factory, complying with international standards like NMPA, FDA, and EMA, has bolstered their manufacturing capabilities.

Looking ahead, Mabwell aims to continue pioneering novel therapies and contributing to global healthcare with its vision of ‘Innovation, from ideas to reality.’ Their dedication to pushing boundaries in drug development underscores their mission to ‘Explore Life, Benefit Health.’